NASDAQ:ETON

Eton Pharmaceuticals Stock Forecast, Price & News

$5.39

-0.26 (-4.60 %)

(As of 07/27/2021 12:00 AM ET)

Add

Compare

Today's Range

$5.37

▼

$5.68

50-Day Range

$5.39

▼

$8.85

52-Week Range

$5.21

▼

$10.30

Volume124,380 shs

Average Volume380,546 shs

Market Capitalization$132.10 million

P/E RatioN/A

Dividend YieldN/A

Beta1.26

30 days | 90 days | 365 days | Advanced Chart

Receive ETON News and Ratings via Email

Sign-up to receive the latest news and ratings for Eton Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. It also develops ET-105, a lamotrigine for oral suspension; DS-300, a cysteine injection; DS-100, a dehydrated alcohol injection; ET-104, a zonisamide oral suspension; ET-101, a topiramate oral suspension; and ET-203, an ephedrine ready-to-use injection. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Major Shareholder Sells $151,274.00 in Stock
July 19, 2021 | americanbankingnews.com

Cerevel Therapeutics Holdings Inc.
July 17, 2021 | wsj.com

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Sees Large Decrease in Short Interest
July 16, 2021 | americanbankingnews.com

Unusual Options Activity Insight: Eton Pharmaceuticals
July 16, 2021 | benzinga.com

Opaleye Management Inc. Sells 105,000 Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock
July 15, 2021 | americanbankingnews.com

Short Interest in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Grows By 21.6%
July 4, 2021 | americanbankingnews.com

Where Do Hedge Funds Stand On Eton Pharmaceuticals, Inc. (ETON)?
June 28, 2021 | finance.yahoo.com

Eton Pharmaceuticals Buys US, Canadian Rights To Zeneo Hydrocortisone Autoinjector
June 16, 2021 | finance.yahoo.com

CROSSJECT : US & Canada licensing agreement with Eton Pharmaceuticals for Crossject’s ZENEO® Hydrocortisone
June 16, 2021 | uk.finance.yahoo.com

Eton Pharmaceuticals Gets FDA Approval of Rezipres >ETON
June 15, 2021 | marketwatch.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ETON
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.etonpharma.com
Phone847-787-7361
Employees16
Year FoundedN/A

Sales & Book Value

Annual Sales$40,000.00
Price / Sales3,302.45
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.65 per share
Price / Book8.29

Profitability

EPS (Most Recent Fiscal Year)($1.33)
Net Income$-27,970,000.00
Net MarginsN/A
Return on Equity-121.00%
Return on Assets-66.16%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares24,508,000
Market Cap$132.10 million
Next Earnings Date8/11/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

2.05 out of 5 stars

Medical Sector

255th out of 2,218 stocks

Pharmaceutical Preparations Industry

119th out of 869 stocks

3.5 Analyst's Opinion

Consensus Rating
Eton Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.50, Eton Pharmaceuticals has a forecasted upside of 131.9% from its current price of $5.39.
Amount of Analyst Coverage
Eton Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

3.2 Community Rank

Outperform Votes
Eton Pharmaceuticals has received 76 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Eton Pharmaceuticals has received 41 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Eton Pharmaceuticals has received 64.96% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Eton Pharmaceuticals and other stocks. Vote “Outperform” if you believe ETON will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ETON will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Eton Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Eton Pharmaceuticals does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Eton Pharmaceuticals insiders have sold 4,863.69% more of their company's stock than they have bought. Specifically, they have bought $29,800.00 in company stock and sold $1,479,180.00 in company stock.
Percentage Held by Insiders
Only 12.92% of the stock of Eton Pharmaceuticals is held by insiders.
Percentage Held by Institutions
35.86% of the stock of Eton Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9 Earnings and Valuation

Earnings Growth
Earnings for Eton Pharmaceuticals are expected to grow by 26.09% in the coming year, from $0.23 to $0.29 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Eton Pharmaceuticals is -8.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Eton Pharmaceuticals is -8.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Eton Pharmaceuticals has a P/B Ratio of 8.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Eton Pharmaceuticals (NASDAQ:ETON) Frequently Asked Questions

Is Eton Pharmaceuticals a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eton Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Eton Pharmaceuticals stock.
View analyst ratings for Eton Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Eton Pharmaceuticals?

Wall Street analysts have given Eton Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Eton Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Eton Pharmaceuticals?

Eton Pharmaceuticals saw a drop in short interest in the month of June. As of June 30th, there was short interest totaling 1,390,000 shares, a drop of 22.8% from the June 15th total of 1,800,000 shares. Based on an average trading volume of 633,700 shares, the short-interest ratio is presently 2.2 days. Currently, 6.9% of the company's shares are sold short.
View Eton Pharmaceuticals' Short Interest.

When is Eton Pharmaceuticals' next earnings date?

Eton Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Eton Pharmaceuticals.

How were Eton Pharmaceuticals' earnings last quarter?

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) released its quarterly earnings results on Thursday, May, 13th. The company reported $0.19 earnings per share for the quarter, meeting the Zacks' consensus estimate of $0.19. The company earned $11.90 million during the quarter, compared to analyst estimates of $12.05 million.
View Eton Pharmaceuticals' earnings history.

How has Eton Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Eton Pharmaceuticals' stock was trading at $4.20 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ETON shares have increased by 28.3% and is now trading at $5.39.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ETON?

2 brokers have issued 1-year target prices for Eton Pharmaceuticals' shares. Their forecasts range from $11.00 to $14.00. On average, they expect Eton Pharmaceuticals' share price to reach $12.50 in the next year. This suggests a possible upside of 131.9% from the stock's current price.
View analysts' price targets for Eton Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Eton Pharmaceuticals' key executives?

Eton Pharmaceuticals' management team includes the following people:

Mr. Sean E. Brynjelsen, Pres, CEO & Director (Age 49, Pay $705.93k)
Mr. W. Wilson Troutman CPA, CFO, Treasurer & Sec. (Age 67, Pay $396.48k)
Mr. Paul Stickler, Sr. VP of Sales & Marketing
Ms. Bharathi Devarakonda, Sr. VP of Regulatory Affairs & Product Devel.
Ms. Ingrid Hoos, Sr. VP of Regulatory Affairs
Mr. Scott Grossenbach, VP of Sales & Marketing
Mr. David Krempa CFA, VP of Bus. Devel.

Who are some of Eton Pharmaceuticals' key competitors?

Some companies that are related to Eton Pharmaceuticals include Greenwich LifeSciences (GLSI), VistaGen Therapeutics (VTGN), Spectrum Pharmaceuticals (SPPI), AC Immune (ACIU), Werewolf Therapeutics (HOWL), Vaccitech (VACC), Imago BioSciences (IMGO), DiaMedica Therapeutics (DMCAF), Clovis Oncology (CLVS), Aldeyra Therapeutics (ALDX), KalVista Pharmaceuticals (KALV), Evelo Biosciences (EVLO), Basilea Pharmaceutica (BPMUF), Lexicon Pharmaceuticals (LXRX) and ZIOPHARM Oncology (ZIOP).
View all of ETON's competitors.

What other stocks do shareholders of Eton Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eton Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Myovant Sciences (MYOV), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC) and Moderna (MRNA).

When did Eton Pharmaceuticals IPO?

(ETON) raised $22 million in an initial public offering (IPO) on Wednesday, November 14th 2018. The company issued 3,600,000 shares at a price of $6.00 per share. National Securities Corporation acted as the underwriter for the IPO.

What is Eton Pharmaceuticals' stock symbol?

Eton Pharmaceuticals trades on the NASDAQ under the ticker symbol "ETON."

How do I buy shares of Eton Pharmaceuticals?

Shares of ETON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eton Pharmaceuticals' stock price today?

One share of ETON stock can currently be purchased for approximately $5.39.

How much money does Eton Pharmaceuticals make?

Eton Pharmaceuticals has a market capitalization of $132.10 million and generates $40,000.00 in revenue each year. The company earns $-27,970,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis.

How many employees does Eton Pharmaceuticals have?

Eton Pharmaceuticals employs 16 workers across the globe.

What is Eton Pharmaceuticals' official website?

The official website for Eton Pharmaceuticals is www.etonpharma.com.

Where are Eton Pharmaceuticals' headquarters?

Eton Pharmaceuticals is headquartered at 21925 W. FIELD PARKWAY SUITE 235, DEER PARK IL, 60010.

How can I contact Eton Pharmaceuticals?

Eton Pharmaceuticals' mailing address is 21925 W. FIELD PARKWAY SUITE 235, DEER PARK IL, 60010. The company can be reached via phone at 847-787-7361 or via email at [email protected]

This page was last updated on 7/27/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here